Medically reviewed on May 23, 2017.
Applies to the following strengths: 300 mg; 400 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Multiple Myeloma
10 mg/kg IV every week for the first 2 cycles and every 2 weeks thereafter until disease progression or unacceptable toxicity:
-Cycles 1 and 2: 10 mg/kg IV once a week on days 1, 8, 15, and 22 of a 28-day cycle
-Cycle 3 and beyond: 10 mg/kg IV once every 2 weeks on days 1 and 15 of a 28-day cycle
Manufacturer recommended infusion rate (at the recommended concentration of 25 mg/mL):
CYCLE 1, DOSE 1:
-Time interval 0 to 30 min; Rate 0.5 mL/min
-Time interval 30 to 60 min; Rate 1 mL/min
-Time interval 60 min or more; Rate 2 mL/min
CYCLE 1, DOSE 2:
-Time interval 0 to 30 min; Rate 3 mL/min
-Time interval 30 min or more; Rate 4 mL/min
CYCLE 1, DOSE 3 AND 4 AND ALL SUBSEQUENT CYCLES:
-Rate 5 mL/min
-The length of a cycle is 28 days.
-This drug is given in combination with lenalidomide and dexamethasone; refer to the dexamethasone and lenalidomide prescribing information for additional information.
-Patients should be premedicated 45 to 90 minutes before administration of elotuzumab with dexamethasone, an antipyretic, an H1 blocker, and an H2 blocker. The manufacturer recommends: Dexamethasone 28 mg orally 3 to 24 hours before the elotuzumab infusion plus dexamethasone 8 mg IV 45 to 90 minutes prior to infusion; on days that elotuzumab is not administered but dexamethasone is due (e.g., days 8 and 22 of cycle 3 and beyond), administer the standard dexamethasone dose (40 mg orally) AND acetaminophen 650 to 1000 mg orally AND diphenhydramine 25 to 50 mg orally or IV (or equivalent H1 blocker) AND ranitidine 50 mg IV or 150 mg orally (or equivalent H2 blocker).
Use: In combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received 1 to 3 prior therapies
Renal Dose Adjustments
No adjustment recommended for any stage of renal impairment.
Liver Dose Adjustments
Liver enzymes should be monitored and dosing should be adjusted if needed.
If the dose of one drug in the regimen is delayed, interrupted, or discontinued, the treatment with the other drugs may continue as scheduled; however, if dexamethasone is delayed or discontinued, the decision on whether to administer elotuzumab should be based on clinical judgment (i.e., risk of hypersensitivity).
If a Grade 2 or higher infusion reaction occurs, interrupt the infusion and institute appropriate medical measures. Upon resolution to Grade 1 or lower, restart elotuzumab at 0.5 mL per minute and gradually increase at a rate of 0.5 mL per minute every 30 minutes as tolerated to the rate at which the infusion reaction occurred. Resume the escalation regimen if there is no recurrence of the infusion reaction. Vital signs should be monitored every 30 minutes during and for 2 hours after the end of the infusion in patients who experience an infusion reaction. If the reaction recurs, stop the infusion and do not restart on that day. Severe infusion reactions may require permanent discontinuation of therapy and emergency treatment. Dose delays and modifications for dexamethasone and lenalidomide should be performed as recommended in their manufacturer prescribing information.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
This drug is not removed by dialysis.
-The manufacturer product information should be consulted.
-Store under refrigeration at 2C to 8C (36F to 46F).
-Protect from light by storing in the original package until time of use.
-Do not freeze or shake.
-Instruct the patient to read the approved patient labeling.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about elotuzumab
- Elotuzumab Side Effects
- During Pregnancy
- Drug Interactions
- En Español
- Drug class: miscellaneous antineoplastics
Other brands: Empliciti